A Randomized Phase 2 Trial of Lenalidomide/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide Followed by Lenalidomide/ Dexamethasone/Elotuzumab Maintenance as Second-Line Therapy for Patients With Relapsed AL Amyloidosis
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- 07 Sep 2017 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
- 07 Sep 2017 Planned primary completion date changed from 6 Dec 2019 to 30 Sep 2019.
- 23 Aug 2017 New trial record